# PT-141 FAQ: Bremelanotide Questions Answered, Cited to Source

> PT-141 questions answered: what it is, how it works, whether it is approved for men, dosing, and side effects. Bremelanotide facts from the trials and the label.

Definitions, mechanism, the approved indication, the off-label male research, dosing, and side effects — each answered directly and cited where it makes a quantitative claim.

## What is PT-141 used for?

PT-141 (bremelanotide) is FDA-approved (2019) only for acquired, generalized HSDD — persistently low sexual desire causing distress — in premenopausal women, given as a 1.75 mg subcutaneous injection as needed [3][6]. Every other use, including in men and for erectile dysfunction, is off-label and not supported by the approval.

## Does PT-141 work through the brain or through blood flow?

Through the brain. PT-141 activates central melanocortin receptors — chiefly MC4R — in hypothalamic and limbic circuits tied to sexual desire [1]. That is unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle to affect blood flow. The mechanism is central motivation, not local circulation [1].

## What is PT-141?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide (a seven-amino-acid ring) analogue of alpha-MSH that acts as a melanocortin (MC3R/MC4R) receptor agonist [1]. It was first studied in sexual dysfunction and is now an FDA-approved drug for one specific indication [6].

## What is PT-141 peptide?

The PT-141 peptide is a seven-amino-acid cyclic peptide whose ring structure, closed by a lactam bridge, improves stability over linear melanocortin peptides [1][6]. It is the same molecule approved as bremelanotide. Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH; molecular weight 1025.2 Da [6].

## What does the PT-141 peptide do?

It activates central melanocortin receptors — chiefly MC4R — in brain circuits governing sexual desire and arousal [1]. That central action is the basis for its approved use in premenopausal women with HSDD and for its off-label sexual-function research in men [3][6]. It does not act on blood vessels.

## Is PT-141 the same as bremelanotide?

Yes. "PT-141" is the original research code; "bremelanotide" is the international nonproprietary name (INN) of the approved drug [6]. They refer to the identical molecule (CAS 189691-06-3), approved under NDA 210557 in June 2019 [6].

## What is bremelanotide?

Bremelanotide is the FDA-approved (2019) melanocortin receptor agonist for acquired, generalized HSDD in premenopausal women — the same compound studied as PT-141 [6]. It is given as a 1.75 mg subcutaneous injection, as needed, and is the drug tested in the two RECONNECT Phase 3 trials [3][6].

## How does PT-141 work?

By stimulating MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, engaging dopaminergic pathways linked to sexual motivation, rather than acting on blood vessels [1]. Animal and fMRI data both support this central mechanism [1][5]. It is a brain-circuit drug, not a blood-flow drug.

## What receptors does PT-141 act on?

Primarily the melanocortin 4 receptor (MC4R), with secondary MC3R activity [1]. Peripheral MC1R activation in skin is linked to hyperpigmentation with repeated dosing [6][12]. The central MC3R/MC4R action is what drives the sexual-function effect [1].

## What is a melanocortin receptor agonist?

A molecule that activates melanocortin receptors (MC1R-MC5R), a family of G-protein-coupled receptors responding to peptides like alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes. An agonist switches a receptor on, as opposed to blocking it [1].

## Does PT-141 increase testosterone?

No. PT-141 does not act through the HPG (hypothalamic-pituitary-gonadal) axis and does not directly raise testosterone [1]. Its effect is central, via melanocortin receptors in sexual-motivation circuits, not hormonal. This is a common misconception about how the molecule works.

## What does PT-141 do for men?

In early-phase research, systemic PT-141 produced dose-dependent erectile activity in men, including some sildenafil non-responders [1][7]. This use is off-label and investigational, not approved [6]. The current development program studies it co-administered with a PDE-5 inhibitor [14].

## Is PT-141 approved for men?

No. The 2019 FDA approval covers only premenopausal women with HSDD [6]. Male and erectile-dysfunction use is off-label, and the male/erectile evidence is early-phase and investigational, not established [1][7].

## How is PT-141 different from PDE-5 inhibitors?

PT-141 acts centrally on MC4R neural circuits of sexual motivation; PDE-5 inhibitors act peripherally on penile blood flow [1]. The mechanisms are complementary, not interchangeable — early studies even co-administered the two to combine central and peripheral effects [9].

## Does PT-141 nasal spray work?

Early intranasal studies in men showed a statistically significant erectile response above ~7 mg, with onset near 30 minutes [7]. But the intranasal route was discontinued for pharmacokinetic variability in favor of subcutaneous dosing; the approved product is a subcutaneous injection, not a spray [6][7].

## Is PT-141 better than PDE-5 inhibitors for erectile dysfunction?

There is no approval or head-to-head basis to call it better. PT-141 is not approved for ED, and current development studies it co-administered with a PDE-5 inhibitor in non-responders rather than as a replacement [14]. The two act by different mechanisms [1].

## Why is PT-141 being studied with a PDE-5 inhibitor?

Because the mechanisms are complementary: a central melanocortin agonist plus a peripheral PDE-5 inhibitor [1][9]. In June 2024 the developer announced a Phase 2 study (~50 patients) of bremelanotide co-administered with a PDE-5 inhibitor in non-responders [14]. That is a development-status announcement, not a peer-reviewed result.

## What is the PT-141 dosage?

The approved label specifies 1.75 mg subcutaneously as needed, at least 45 minutes before activity, no more than one dose per 24 hours and no more than 8 per month [6]. This is reported as a label finding, not a recommendation for any individual.

## How much PT-141 should I take?

This site does not recommend a dose for anyone. The studied and labeled dose is 1.75 mg subcutaneous as needed; dosing is a clinical decision, and "PT-141 research chemical" is laboratory material, not the approved drug [6]. The figures here are findings, not guidance.

## How much PT-141 to inject?

Trials and the label used 1.75 mg subcutaneously; earlier dose-finding in women tested 0.75, 1.25, and 1.75 mg [3][6]. These are reported findings, not dosing guidance, and this site recommends no dose to any reader [6].

## What is the PT-141 dosage for women?

For the approved HSDD indication in premenopausal women, the label dose is 1.75 mg subcutaneous as needed (maximum one dose per 24 hours, 8 per month) [6]. Stated here strictly as the approved-label finding [3][6].

## How do you reconstitute PT-141?

The approved bremelanotide product is supplied as a ready-to-use subcutaneous autoinjector, not reconstituted [6]. Lyophilized "research chemical" powder is a non-approved laboratory material; this site gives no preparation protocol for human use and recommends no dose [6].

---

The PT-141 (bremelanotide) record printed at billboard scale — the approved-for-women-only indication, the off-label male research, and the nausea-led tolerability set out in plain sight and cited to source; a poster of the evidence, with no clinic behind it and nothing here dispensed or sold.